Dr. Metenou joined Shattuck in September 2022 as Vice President of Translational Medicine. He brings to Shattuck more than 20 years of human immunology research experience in academia and government, as well as biotech and large pharmaceutical companies.  Prior to joining Shattuck, Dr. Metenou held senior leadership roles at Precigen, where he oversaw development of therapeutic vaccines for HPV-positive tumors and associated nonmalignant tumors, in addition to designing correlative studies and biomarker plans for CAR-T therapies in solid tumor and hematological malignancies.  Previously, Dr. Metenou was with Compass Therapeutics and EMD Serono (Merck KGAa), during which time he developed and implemented the biomarker strategy for avelumab.  After earning his PhD in Immunology at Georgetown University, Dr. Metenou completed his post-doctoral fellowship training and was a research fellow at the National Institutes of Infectious Diseases.